MNUFF
MANULIFE FINANCIAL CORP
$14.50
0.00%
No data for this timeframe.
Vol
SEC Reports4
Recent Activity
Jun 5, 2026
SEC
Manulife announced the results of the conversion privileges for its Series 3 and Series 4 preferred shares. Due to insuf
6-K — Impact 3/10
May 26, 2026
SEC
Manulife Financial Corp. priced a S$500 million (approximately US$370 million) offering of 2.880% subordinated notes due
6-K — Impact 3/10
May 14, 2026
SEC
Manulife Financial Corp filed a 6-K reporting voting results from its May 14, 2026 annual meeting. All 13 director nomin
6-K — Impact 2/10
Analyst Ratings
2Strong Buy
12Buy
4Hold
1Sell
0Strong Sell
Latest Reports
NEUTRAL
6-K
3/10
Manulife announced the results of the conversion privileges for its Series 3 and Series 4 preferred shares. Due to insuf
Jun 5, 2026
NEUTRAL
6-K
3/10
Manulife Financial Corp. priced a S$500 million (approximately US$370 million) offering of 2.880% subordinated notes due
May 26, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 2.5/10.
NEUTRAL
6-K
3/10
Manulife announced the results of the conversion privileges for its Series 3 and Series 4 preferred
Jun 5, 2026
NEUTRAL
6-K
3/10
Manulife Financial Corp. priced a S$500 million (approximately US$370 million) offering of 2.880% su
May 26, 2026
NEUTRAL
6-K
2/10
Manulife Financial Corp filed a 6-K reporting voting results from its May 14, 2026 annual meeting. A
May 14, 2026
NEUTRAL
6-K
2/10
Manulife Financial Corporation is holding its 2026 annual meeting to elect directors, appoint audito
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 74% buy across 19 analysts — 2 strong buy, 12 buy, 4 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $57.5B | -5.6% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $53.0B | -7.8% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 12 | 4 | 1 | 0 | 74% | |
| May 1, 2026 | 2 | 12 | 4 | 1 | 0 | 74% | |
| Apr 1, 2026 | 2 | 12 | 4 | 1 | 0 | 74% | |
| Mar 1, 2026 | 2 | 12 | 4 | 1 | 0 | 74% | |
| Feb 1, 2026 | 2 | 12 | 4 | 1 | 0 | 74% | |
| Jan 1, 2026 | 2 | 11 | 5 | 1 | 0 | 68% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.